Journal
PHARMACEUTICS
Volume 11, Issue 10, Pages -Publisher
MDPI
DOI: 10.3390/pharmaceutics11100547
Keywords
ovarian cancer; siRNA; polymer; lipid; delivery
Categories
Funding
- Fondazione Benefica Kathleen Foreman Casali of Trieste
- Beneficentia Stiftung of Vaduz Liechtenstein
- FRA 2015, University of Trieste
- POR FESR 2014-2020 FRIULI VENEZIA GIULIA, ATeNA 2017 [J96G17000120005]
- European Social Fund
- European Regional Development Fund-Project MAGNET [CZ.02.1.01/0.0/0.0/15_003/0000492]
Ask authors/readers for more resources
The unmet need for novel therapeutic options for ovarian cancer (OC) deserves further investigation. Among the different novel drugs, small interfering RNAs (siRNAs) are particularly attractive because of their specificity of action and efficacy, as documented in many experimental setups. However, the fragility of these molecules in the biological environment necessitates the use of delivery materials able to protect them and possibly target them to the cancer cells. Among the different delivery materials, those based on polymers and lipids are considered very interesting because of their biocompatibility and ability to carry/deliver siRNAs. Despite these features, polymers and lipids need to be engineered to optimize their delivery properties for OC. In this review, we concentrated on the description of the therapeutic potential of siRNAs and polymer-/lipid-based delivery systems for OC. After a brief description of OC and siRNA features, we summarized the strategies employed to minimize siRNA delivery problems, the targeting strategies to OC, and the preclinical models available. Finally, we discussed the most interesting works published in the last three years about polymer-/lipid-based materials for siRNA delivery.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available